Abstract:
A pharmaceutical composition comprising a lipase inhibitor and a lipophilic oil absorbent is provided to minimize side effects caused by dosage of the lipase inhibitor including oily spotting, oily feces, abdominal distension and gas, so that it is useful for prevention and treatment of obesity and hyperlipidemia. A pharmaceutical composition comprises (a) 100 parts by weight of a lipase inhibitor, (b) 10-5000 parts by weight of a lipophilic oil absorbent selected from hydrogenated castor oil, hydrogenated vegetable oil, glyceryl behenate, glyceryl palmitostearate and a mixture thereof, and (c) a pharmaceutically acceptable additive, wherein the lipase inhibitor is lipstatin, orlistat, panclicins, hesperidin, ebelactones, esterastin and its derivative, valilactone or a pharmaceutically acceptable salt. The hydrogenated vegetable oil is selected from hydrogenated cotton seed oil, hydrogenated palm oil and hydrogenated soybean oil.
Abstract:
A controlled-release preparation containing cilostazol is provided to improve absorption rate of cilostazol in small intestine and reduce side effects such as headache by staying in stomach for a long time and slowly releasing cilostazol, and enhance compliance of patient by reducing dosage frequency. A controlled-release preparation contains 10-80 wt.% of cilostazol or its pharmaceutically acceptable salt, 0.1-50 wt.% of solubilizer, 5-80 wt.% of swelling agent, 0.5-50 wt.% of swelling speed-controller and 0.1-50 wt.% of gas-generating material. A method for preparing the controlled-release preparation containing cilostazol comprises the steps of: mixing cilostazol or its pharmaceutically acceptable salt, solubilizer, swelling agent, swelling speed-controller and gas-generating material; granulating the mixture; and filling the granulates in capsules or tabletting the granulates.